Abstract
Glioblastoma (GBM) is the most common of all highgrade gliomas (HGGs). It accounts for almost 80% of all malignant primary neoplasms of the brain (1). It is a very aggressive tumor, with historical median survival rates of less than 2 years. Patients receiving standard of care following surgical resection, temozolomide (TMZ) plus radiation therapy, have a median survival of 14- 18 months, highlighting the need for developing novel therapeutic strategies to effectively target malignant gliomas while preserving quality of life (2). Malignant gliomas are characterized by cellular heterogeneity, are highly vascularized, and invasive, which influence their resistance to conventional treatments and poor clinical outcomes.
Highlights
Glioblastoma (GBM) is the most common of all highgrade gliomas (HGGs)
Malignant gliomas are characterized by cellular heterogeneity, are highly vascularized, and invasive, which influence their resistance to conventional treatments and poor clinical outcomes
In the past thirteen years, only three therapies have been approved by the FDA for GBM—TMZ, bevacizumab, and tumor-treating fields (TTF)
Summary
Glioblastoma (GBM) is the most common of all highgrade gliomas (HGGs). It accounts for almost 80% of all malignant primary neoplasms of the brain [1]. Title Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic. Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
